These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15054445)

  • 1. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
    Hackshaw A; Sweetenham J; Knight A
    Br J Cancer; 2004 Apr; 90(7):1302-5. PubMed ID: 15054445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
    Zelenetz AD
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
    Pettengell R; Gurney H; Radford JA; Deakin DP; James R; Wilkinson PM; Kane K; Bentley J; Crowther D
    Blood; 1992 Sep; 80(6):1430-6. PubMed ID: 1381626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic model to assess the savings from a clinical application of haematopoietic growth factors.
    Uyl-de Groot CA; Vellenga E; Rutten FF
    Eur J Cancer; 1996 Jan; 32A(1):57-62. PubMed ID: 8695242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
    Schwartzberg LS; Saleh M; Whittaker S; Abella E
    Support Care Cancer; 2014 Jul; 22(7):1833-41. PubMed ID: 24535242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
    Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
    Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.
    Canellos GP
    Ann Oncol; 1994; 5 Suppl 2():121-2. PubMed ID: 8204512
    [No Abstract]   [Full Text] [Related]  

  • 12. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
    Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
    J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
    Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    J Am Geriatr Soc; 2010 Oct; 58(10):1885-95. PubMed ID: 20840455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
    Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
    Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
    Anglin P; Strauss BA; Brandwein JM
    Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
    Rubino C; Laplanche A; Patte C; Michon J
    J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim.
    Schriber J
    Drugs; 2002; 62 Suppl 1():33-46. PubMed ID: 12479593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
    Dranitsaris G; Altmayer C; Quirt I
    Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.